Biotechnology in Germany

Date: November 23, 2016
Pages: 34
Price:
US$ 350.00
License [?]:
Publisher: MarketLine
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: B3F4C8CABE3EN
Leaflet:

Download PDF Leaflet

Biotechnology in Germany
SUMMARY

Biotechnology in Germany industry profile provides top-line qualitative and quantitative summary information including: market size (value 2012-16, and forecast to 2021). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

SYNOPSIS
  • Save time carrying out entry-level research by identifying the size, growth, major segments, and leading players in the biotechnology market in Germany
  • Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the biotechnology market in Germany
  • Leading company profiles reveal details of key biotechnology market players' global operations and financial performance
  • Add weight to presentations and pitches by understanding the future growth prospects of the Germany biotechnology market with five year forecasts
REASONS TO BUY
  • What was the size of the Germany biotechnology market by value in 2016?
  • What will be the size of the Germany biotechnology market in 2021?
  • What factors are affecting the strength of competition in the Germany biotechnology market?
  • How has the market performed over the last five years?
  • What are the main segments that make up Germany's biotechnology market?
KEY HIGHLIGHTS

The biotechnology market consists of the development, manufacturing, and marketing of products based on advanced biotechnology research.

The German biotechnology market is expected to generate total revenues of $8.7bn in 2016, representing a compound annual growth rate (CAGR) of 7% between 2012 and 2016.

The Medical/Healthcare segment is expected to be the market's most lucrative in 2016, with total revenues of $4.3bn, equivalent to 49.7% of the market's overall value.

There is strong interest in the German biotech industry from foreign players. Japanese Astelles Pharma has entered negotiations to buy Ganymed Pharmaceuticals in order to gain access to the highly regarded cancer antibody technology.
Executive Summary
Market value
Market value forecast
Category segmentation
Geography segmentation
Market rivalry
Market Overview
Market definition
Market analysis
Market Data
Market value
Market Segmentation
Category segmentation
Geography segmentation
Market Outlook
Market value forecast
Five Forces Analysis
Summary
Buyer power
Supplier power
New entrants
Threat of substitutes
Degree of rivalry
Leading Companies
Boehringer Ingelheim GmbH
Merck and Co., Inc.
MorphoSys AG
Macroeconomic Indicators
Country data
Methodology
Industry associations
Related MarketLine research
Appendix
About MarketLine

LIST OF TABLES

Table 1: Germany biotechnology industry value: $ million, 2012-16(e)
Table 2: Germany biotechnology industry category segmentation: $ million, 2016(e)
Table 3: Germany biotechnology industry geography segmentation: $ billion, 2016(e)
Table 4: Germany biotechnology industry value forecast: $ million, 2016-21
Table 5: Boehringer Ingelheim GmbH: key facts
Table 6: Boehringer Ingelheim GmbH: key financials ($)
Table 7: Boehringer Ingelheim GmbH: key financials (€)
Table 8: Boehringer Ingelheim GmbH: key financial ratios
Table 9: Merck and Co., Inc.: key facts
Table 10: Merck and Co., Inc.: key financials ($)
Table 11: Merck and Co., Inc.: key financial ratios
Table 12: MorphoSys AG: key facts
Table 13: MorphoSys AG: key financials ($)
Table 14: MorphoSys AG: key financials (€)
Table 15: MorphoSys AG: key financial ratios
Table 16: Germany size of population (million), 2012-16
Table 17: Germany gdp (constant 2005 prices, $ billion), 2012-16
Table 18: Germany gdp (current prices, $ billion), 2012-16
Table 19: Germany inflation, 2012-16
Table 20: Germany consumer price index (absolute), 2012-16
Table 21: Germany exchange rate, 2012-16


LIST OF FIGURES

Figure 1: Germany biotechnology industry value: $ million, 2012-16(e)
Figure 2: Germany biotechnology industry category segmentation: % share, by value, 2016(e)
Figure 3: Germany biotechnology industry geography segmentation: % share, by value, 2016(e)
Figure 4: Germany biotechnology industry value forecast: $ million, 2016-21
Figure 5: Forces driving competition in the biotechnology industry in Germany, 2016
Figure 6: Drivers of buyer power in the biotechnology industry in Germany, 2016
Figure 7: Drivers of supplier power in the biotechnology industry in Germany, 2016
Figure 8: Factors influencing the likelihood of new entrants in the biotechnology industry in Germany, 2016
Figure 9: Factors influencing the threat of substitutes in the biotechnology industry in Germany, 2016
Figure 10: Drivers of degree of rivalry in the biotechnology industry in Germany, 2016
Figure 11: Boehringer Ingelheim GmbH: revenues and profitability
Figure 12: Boehringer Ingelheim GmbH: assets and liabilities
Figure 13: Merck and Co., Inc.: revenues and profitability
Figure 14: Merck and Co., Inc.: assets and liabilities
Figure 15: MorphoSys AG: revenues and profitability
Figure 16: MorphoSys AG: assets and liabilities


COMPANIES MENTIONED

Boehringer Ingelheim GmbH
Merck and Co., Inc.
MorphoSys AG
Skip to top


Ask Your Question

Biotechnology in Germany
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: